Latest Biotech News

Takeda began workforce reductions in the U.S. tied to a multiyear restructuring plan aimed at more than ¥200 billion ($1.26 billion) in annual cost savings. A WARN notice filed in Massachusetts...

ICON partnered with Advarra to build an integrated, AI-driven site network designed to streamline clinical trial operations. The collaboration combines ICON’s trial services with Advarra’s...

Roche Diagnostics received FDA 510(k) clearance for lab automation modules and secured CE marking for a blood donor screening assay. The company’s Cobas c 703 and Cobas ISE Neo units expand the...

Kailera Therapeutics filed for an IPO as it seeks additional funding to advance a late-stage obesity pipeline, including ribupatide, a weekly GLP-1/GIP agonist. The company plans to list on Nasdaq...

Viridian Therapeutics’ thyroid eye disease (TED) program delivered a phase 3 win, though investors still face questions about commercial positioning. In the REVEAL-1 study of 132 patients,...

Connect Biopharma reported positive phase 3 results for its eczema drug candidate in a 52-week dataset, positioning the company’s therapy as a potential Dupixent challenger. The update centers on...

Alamar Biosciences filed for an IPO, seeking to bring its proteomics and immunoassay platform to public markets. The company plans to list on Nasdaq under ticker “ALMR,” and reported revenue...

Royalty Pharma agreed to co-fund Johnson & Johnson’s $500 million autoimmune antibody program, marking another expansion of Royalty’s royalty-backed development model in immunology. The...

Roche won FDA clearance for two Cobas Pro lab automation units and secured CE marking for a blood donor screening assay, expanding its push to boost high-throughput testing with modular platforms....

Eli Lilly agreed to pay Insilico Medicine $115 million upfront and structured the deal for up to about $2.75 billion in additional payments tied to development, regulatory and commercial...

Connect Biopharma reported multi-endpoint improvements in a Phase 3 eczema trial and said its dupilumab-like competitor achieved 52-week gains, supporting the company’s view that its approach can...

Viridian Therapeutics reported a Phase 3 win for elegrobart, an anti-IGF-1R antibody in thyroid eye disease, and said the program hit its primary endpoint in REVEAL-1. The study enrolled 132...

Rocket Pharmaceuticals received FDA approval for Kresladi, positioning the therapy as the first commercial gene therapy for leukocyte-adhesion deficiency type 1, an ultra-rare inherited...

Wave Life Sciences shares dropped sharply after the company reported mixed early clinical data for WVE-007, its RNA-based obesity candidate, in the Phase I INLIGHT trial. Investors focused on...

At ACC26, Merck signaled it is leaning toward a lower Winrevair dose for a pivotal Phase 3 program after seeing what it called a “pretty profound” benefit at the lowest dose in a prior Phase 2...

Biogen reported additional Phase 2 lupus results for litifilimab, describing improvements in skin lesions that strengthen momentum toward potentially pivotal readouts. The company said the therapy...

Takara Bio USA and Hamilton announced a partnership to develop and co-market automated NGS library prep workflows using Hamilton’s Microlab Star platform. The companies plan to automate Takara’s...

Everlywell and Jona teamed up to expand consumer access to a gut microbiome test through Everlywell’s digital health platform. The partnership aims to increase reach for Jona’s microbiome offering...

Rocket Pharmaceuticals has won FDA approval for Kresladi, a gene therapy for leukocyte-adhesion deficiency type 1 (LAD-1), an inherited immunodeficiency that can be fatal in early childhood. The...

Kardigan reported mixed Phase 2 results for tonlamarsen (licensed from Ionis Pharmaceuticals) in uncontrolled hypertension: the antisense oligonucleotide reduced angiotensinogen (AGT) by Week 20,...